MedPath

FDA Approves Roche's Ocrevus Zunovo for Multiple Sclerosis with Halozyme's Enhanze Technology

• The FDA has approved Roche's Ocrevus Zunovo, a subcutaneous formulation for relapsing and primary progressive multiple sclerosis, utilizing Halozyme's Enhanze drug delivery technology. • Ocrevus Zunovo offers a twice-yearly, approximately ten-minute subcutaneous injection, providing greater flexibility for healthcare providers and patients based on individual needs. • The approval is based on the Phase III OCARINA II trial, which demonstrated non-inferior levels of Ocrevus in the bloodstream and comparable safety and efficacy to the intravenous formulation. • The trial showed a 97% effectiveness rate in suppressing relapse activity and MRI lesions through 48 weeks, with over 92% of participants reporting satisfaction with the subcutaneous administration.

Roche has received FDA approval for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous formulation utilizing Halozyme Therapeutics' Enhanze drug delivery technology, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This new formulation offers a twice-yearly, approximately ten-minute subcutaneous injection as an alternative to the intravenous formulation.
Levi Garraway, Roche's chief medical officer and head of global product development, stated that this approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs.

Enhanze Technology Facilitates Subcutaneous Delivery

Ocrevus Zunovo combines Ocrevus with Enhanze drug delivery technology. Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells, which are implicated in causing damage to myelin and axons in multiple sclerosis. Enhanze technology utilizes recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily breaks down hyaluronan in the subcutaneous tissue, increasing tissue permeability and enabling easier and more rapid dispersion and absorption of Ocrevus into the bloodstream.

Clinical Trial Results

The FDA's approval was based on the Phase III OCARINA II trial, which demonstrated non-inferior levels of Ocrevus in the bloodstream when administered subcutaneously compared to the intravenous formulation. The trial also confirmed a comparable safety and efficacy profile between the two approaches for individuals with RMS and PPMS. Exploratory outcomes of the trial revealed that Ocrevus Zunovo matched the intravenous version in suppressing relapse activity and MRI lesions through 48 weeks, with a 97% effectiveness rate for both measures. More than 92% of participants in the trial reported satisfaction with the subcutaneous administration of Ocrevus Zunovo.

Administration and Monitoring

After the first dose, treatment duration with Ocrevus Zunovo could be as short as 55 minutes. Patients are required to take premedications at least 30 minutes before each dose. After the first dose, patients will be monitored by their healthcare provider for a minimum of 60 minutes. For all subsequent doses, patients will be observed for at least 15 minutes post-injection. The most common adverse events associated with Ocrevus Zunovo were injection reactions, which were generally mild or moderate and did not lead to treatment withdrawal.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Zorevunersen Receives FDA Breakthrough Therapy Designation for Dravet Syndrome

Stoke Therapeutics' zorevunersen has received FDA Breakthrough Therapy Designation for Dravet syndrome with confirmed SCN1A gene mutation.
Clinical data from Phase 1/2a and open-label extension studies demonstrated substantial seizure reduction and improvements in cognition and behavior.

FDA Approves Subcutaneous Ocrevus Zunovo for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) as a twice-yearly, 10-minute subcutaneous injection for both relapsing and primary-progressive multiple sclerosis.
Approval was based on the Phase III OCARINA II trial, which demonstrated equivalent drug levels, comparable safety, and high patient satisfaction compared to intravenous Ocrevus.

FDA Approves Subcutaneous Ocrevus Zunovo for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo, a subcutaneous formulation of ocrelizumab, for all forms of multiple sclerosis, including relapsing MS and primary progressive MS.
Ocrevus Zunovo offers a quicker 10-minute injection compared to the 2-4 hour intravenous infusion required for the original Ocrevus formulation.

FDA Approves Ocrevus ZUNOVO: First Subcutaneous Injection for Multiple Sclerosis

The FDA has approved Ocrevus ZUNOVO as the first and only twice-yearly, 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis.
Ocrevus ZUNOVO offers an alternative administration method, potentially expanding treatment access to centers with IV constraints or limited infrastructure.

FDA Approves Roche's Ocrevus ZUNOVO for Relapsing and Progressive Multiple Sclerosis

The FDA has approved Ocrevus ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Ocrevus ZUNOVO is administered via a roughly 10-minute subcutaneous injection twice a year by a healthcare professional.

FDA Approves Ocrevus Zunovo as First Subcutaneous Option for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo, a subcutaneous formulation of ocrelizumab, for relapsing and primary progressive multiple sclerosis.
Ocrevus Zunovo offers a twice-yearly, 10-minute injection, providing an alternative to intravenous infusions.

FDA Approves Genentech's Ocrevus Zunovo as First Twice-Yearly Subcutaneous MS Treatment

The FDA has approved Ocrevus Zunovo, a subcutaneous injection, for relapsing and primary progressive multiple sclerosis.
Ocrevus Zunovo is the first and only twice-a-year, 10-minute subcutaneous treatment option for both forms of MS.

FDA Approves Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis

The FDA has approved subcutaneous ocrelizumab (Ocrevus Zunovo) for relapsing and primary progressive multiple sclerosis (MS).
Ocrevus Zunovo offers a new twice-yearly, 10-minute injection option, providing greater flexibility for patients and healthcare providers.

FDA Approves Roche's Injectable Ocrevus for Multiple Sclerosis

The FDA has approved Roche's subcutaneous injectable version of Ocrevus for treating multiple sclerosis, offering a quicker 7-minute administration time.
The approval was based on the OCARINA II trial, demonstrating non-inferiority to the intravenous formulation regarding drug levels and similar safety profiles.

FDA Approves Genentech's Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Immunotherapy

The FDA has approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab, marking the first subcutaneous anti-PD-(L)1 cancer immunotherapy in the U.S.
Tecentriq Hybreza reduces treatment time to approximately 7 minutes via subcutaneous injection, compared to 30-60 minutes for intravenous infusion.

Reference News

[1]
FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech
finance.yahoo.com · Sep 16, 2024

Roche's Ocrevus Zunovo, combining Ocrevus with Halozyme's Enhanze drug delivery tech, receives FDA approval for subcutan...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy